These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 30953753)

  • 1. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
    Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
    Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Copies of nonbiological complex drugs: generic, hybrid or biosimilar?
    Rocco P; Musazzi UM; Franzè S; Minghetti P
    Drug Discov Today; 2019 Jan; 24(1):250-255. PubMed ID: 30086403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The similarity question for biologicals and non-biological complex drugs.
    Crommelin DJ; Shah VP; Klebovich I; McNeil SE; Weinstein V; Flühmann B; Mühlebach S; de Vlieger JS
    Eur J Pharm Sci; 2015 Aug; 76():10-7. PubMed ID: 25912826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Non-biological Complex Drugs (NBCDs): Complex Pharmaceuticals in Need of Individual Robust Clinical Assessment Before Any Therapeutic Equivalence Decision.
    Gaspar RS; Silva-Lima B; Magro F; Alcobia A; da Costa FL; Feio J
    Front Med (Lausanne); 2020; 7():590527. PubMed ID: 33330550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complex Generic Products: Insight of Current Regulatory Frameworks in US, EU and Canada and the Need of Harmonisation.
    Lunawat S; Bhat K
    Ther Innov Regul Sci; 2020 Sep; 54(5):991-1000. PubMed ID: 31960290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glatiramer acetate: A complex drug beyond biologics.
    Rocco P; Eberini I; Musazzi UM; Franzè S; Minghetti P
    Eur J Pharm Sci; 2019 May; 133():8-14. PubMed ID: 30902653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory considerations for generic products of non-biological complex drugs.
    Liu YH; Chen YS; Tseng T; Jiang ML; Gau CS; Chang LC
    J Food Drug Anal; 2023 Mar; 31(1):20-31. PubMed ID: 37224550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scientific considerations for complex drugs in light of established and emerging regulatory guidance.
    Holloway C; Mueller-Berghaus J; Lima BS; Lee SL; Wyatt JS; Nicholas JM; Crommelin DJ
    Ann N Y Acad Sci; 2012 Dec; 1276():26-36. PubMed ID: 23193987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of biosimilars and non-biologic complex drugs in Europe, the United States, and Canada and their relevance to multiple sclerosis.
    Gran-Ruaz S; Mani A; O'Quinn S
    Mult Scler; 2017 Dec; 23(14):1824-1829. PubMed ID: 29095099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory Science Approach in Pharmaceutical Development of Follow-on Versions of Non-Biological Complex Drug Products.
    Zagalo DM; Simões S; Sousa J
    J Pharm Sci; 2022 Oct; 111(10):2687-2713. PubMed ID: 35901943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider.
    Schellekens H; Stegemann S; Weinstein V; de Vlieger JS; Flühmann B; Mühlebach S; Gaspar R; Shah VP; Crommelin DJ
    AAPS J; 2014 Jan; 16(1):15-21. PubMed ID: 24065600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Therapeutic Equivalence for the Follow-On Version of Intravenously Administered Non-Biological Complex Drugs.
    Sun Z; Jiang J; Chen X
    Clin Pharmacokinet; 2020 Aug; 59(8):995-1004. PubMed ID: 32328977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Do Hospital Pharmacists Approach Substitution of Nanomedicines? Insights from a Qualitative Pilot Study and a Quantitative Market Research Analysis in Five European Countries.
    Sofia N; Mühlebach S; Musazzi UM; Khatib R; Martinez Sesmero JM; Lipp HP; Surugue J; Di Francesco T; Flühmann B
    Pharmaceutics; 2021 Jul; 13(7):. PubMed ID: 34371701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and regulation of biosimilars: current status and future challenges.
    Tsiftsoglou AS; Ruiz S; Schneider CK
    BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
    Hussaarts L; Mühlebach S; Shah VP; McNeil S; Borchard G; Flühmann B; Weinstein V; Neervannan S; Griffiths E; Jiang W; Wolff-Holz E; Crommelin DJA; de Vlieger JSB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):39-49. PubMed ID: 28445611
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From bioequivalence to biosimilars: How much do regulators dare?
    Weise M
    Z Evid Fortbild Qual Gesundhwes; 2019 Mar; 140():58-62. PubMed ID: 30622000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle iron medicinal products - Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies.
    Borchard G; Flühmann B; Mühlebach S
    Regul Toxicol Pharmacol; 2012 Nov; 64(2):324-8. PubMed ID: 22951348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biosimilars].
    Krämer I
    Ther Umsch; 2011 Nov; 68(11):659-66. PubMed ID: 22045529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
    Ahmed I; Kaspar B; Sharma U
    Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic polypeptides using a biologic as a reference medicinal product - the European landscape of regulatory approvals.
    Klein K; Heisterberg J; Stolk P
    Front Med (Lausanne); 2024; 11():1335928. PubMed ID: 38681047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.